Web Results


Hello everyone, this is the first time I have posted a question. Last year I tested RNA Poly 3 "weakly positive". I have Raynaud's, joint issues and shortness of breath. Recently I had a "mildly elevated inflammatory marker" with my C reactive protein lab. I have read that RNA Polymerase III is directly related to Systemic Scleroderma.


The presence of circulating antinuclear antibodies (ANA) is one of the distinctive features of systemic sclerosis (SSc), or scleroderma. A variety of SSc-related ANA, including anticentromere antibody (ACA), antitopoisomerase I antibody (anti–topo I), and anti-RNA polymerase (RNAP) III antibody, have been well characterized and are used in our daily clinical practice. They are specific to ...


RNA polymerase III IgG antibody occur in about 11-23 percent of SSc patients, and typically in the absence of anti-centromere and anti-Scl-70 antibodies. A negative result indicates no detectable IgG antibodies to the dominant antigen of RNA polymerase III and does not rule out the possibility of SSc.


Hi Ruth, I also tested positive for RNA Polymerase about a year and a half ago and was diagnosed with SSc. I had read a bit about scleroderma and the different autoantibodies and was quite scared to come back positive on this one, so I know how you must be feeling.


Negative-sense viral RNA is complementary to mRNA and thus must be converted to positive-sense RNA by an RNA-dependent RNA polymerase before translation. As such, purified RNA of a positive-sense virus can directly cause infection though it may be less infectious than the whole virus particle.


A positive result indicates the presence of measurable IgG antibodies to RNA polymerase III, but does not unequivocally establish the diagnosis of systemic sclerosis or other autoimmune disease. The level of RNA polymerase III autoantibodies does not indicate the severity of disease in patients with systemic sclerosis.


In particular, anti-RNA polymerase III (anti-RNAP III) has been associated with diffuse cutaneous disease, scleroderma renal crisis, a temporal relationship with malignancy, myositis, synovitis, joint contractures, and gastric antral vascular ectasia. However, anti-RNAP III has not been associated with systemic sclerosis sine scleroderma.


The presence of RNA polymerase III IgG antibody, when considered in conjunction with other laboratory and clinical findings, is an aid in the diagnosis of systemic sclerosis (SSc) with increased incidence of skin involvement and renal crisis with the diffuse cutaneous form of SSc.


RNA polymerase (ribonucleic acid polymerase), abbreviated RNAP or RNApol, officially DNA-directed RNA polymerase, is an enzyme that synthesizes RNA from a DNA template. RNAP locally opens the double-stranded DNA (usually about four turns of the double helix) so that one strand of the exposed nucleotides can be used as a template for the synthesis of RNA, a process called transcription.


There is a close temporal relationship between onset of cancer and scleroderma in patients with antibodies to RNA polymerase I/III, which is distinct from scleroderma patients with other autoantibody specificities. In this study, autoantibody response and tumor antigen expression are associated.